Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10424)	10/30/1997 5:09:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>Andy, SRGN is trading around $0.50. If the DAB protein looked good, LGND could just buy SRGN. Is there any competion between SRGN's products and XOMA's?<< I don't see any competition between the DAB protein and Xoma. What makes you ask? Copied the paragraph below from a press release. You are correct that this seems to fit in well with LGND's arsenal. However, this is not one of LLY's drugs, although they are in collaboration with SRGN on it. The LGND rlease made it sound like an exclusively LLY drug. If this is the drug in question, are you suggesting that SNRG would be LGND's acquisition. That would mean that in addition to what they are paying LLY for the drug, they have the added expense of buying out SNRG. >>Seragen's principal focus to date has been on cancer and dermatology. The company's most advanced product, IL-2 Fusion Protein, is in Phase III clinical trials for cutaneous T-cell lymphoma, in collaboration with Eli Lilly and Company. Seragen is independently conducting clinical trials of the same product for psoriasis. The company's second product, EGF Fusion Protein, is currently in a Phase I/II clinical trial for non-small cell lung cancer. <<